Voyager Therapeutics, Inc. VYGR
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2015 · data as of November 13, 2026
Voyager Therapeutics, Inc. (VYGR) is a healthcare company listed in the US with a market value of about $108M. In the twelve months to September 30, 2026 it had revenue of $25M and net income of -$105M, a net margin of -416.3%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -25% a year, a 5-year average ROIC of -22%.
About Voyager Therapeutics
Voyager Therapeutics is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2015. Revenue went from $17M in 2015 to $40M in 2025, growth of about 8.8% a year. It was profitable in 2 of the last 10 years in our data. Its share count rose by 53% over three years (dilution for shareholders). It spends 334% of revenue on research and development.
Score: 0.6 / 5
Checks passed
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $25M | $40M | $80M | $250M | $41M | $37M | $171M | $104M | $8M | $10M | $14M |
| Net income | -$105M | -$120M | -$65M | $132M | -$46M | -$71M | $37M | -$44M | -$88M | -$71M | -$40M |
| Free cash flow | -$110M | -$135M | -$19M | $75M | -$15M | -$55M | -$109M | $41M | -$20M | -$65M | -$48M |
| EPS (diluted) | $-1.74 | $-2.04 | $-1.13 | $2.97 | $-1.21 | $-1.89 | $0.98 | $-1.21 | $-2.75 | $-2.64 | $-1.59 |
| Net margin | -416.3% | -296.5% | -81.2% | 52.9% | -113.5% | -190.3% | 21.5% | -41.8% | -1158.8% | -697.6% | -282.6% |
| ROIC | — | -44.8% | -19.2% | 47.0% | -48.9% | -41.8% | 10.7% | -30.5% | -195.7% | -42.4% | -24.0% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Voyager Therapeutics pay a dividend?
Not currently.
Is Voyager Therapeutics a good stock to buy?
We do not give buy or sell advice. Voyager Therapeutics scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.